title: Immunogenetics of cutaneous lupus erythematosus.
abstract: Systemic lupus erythematosus (SLE) is the prototypic autoimmune condition, often affecting multiple organ systems, including the skin. Cutaneous lupus erythematosus (CLE) is distinct from SLE and may be skin limited or associated with systemic disease. Histopathologically, the hallmark of lupus-specific manifestations of SLE and CLE is an interface dermatitis. The cause of SLE and CLE is likely multifactorial and may include shared genetic factors. In this review, we will discuss the genetic findings related to the cutaneous manifestations of SLE and isolated CLE, with a particular focus on the lupus-specific CLE subtypes.
  
  
  
  Several major histocompatibility complex and nonmajor histocompatibility complex genetic polymorphisms have been identified which may contribute to the cutaneous manifestations of SLE and to CLE. Most of these genetic variants are associated with mechanisms attributed to the pathogenesis of SLE, including pathways involved in interferon and vitamin D regulation and ultraviolet light exposure. Although there is overlap between the genetic factors associated with SLE and CLE, there appear to be unique genetic factors specific for CLE.
  
  
  
  Improved understanding of the genetics of CLE may lead to the creation of targeted therapies, improving outcomes for patients with this challenging dermatologic condition.
authors.affiliation: aDepartment of Pediatrics, University of Utah School of Medicine, Salt Lake City, UtahbDepartments of Dermatology and Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USAcDepartments of Pediatrics and Human Genetics, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia.
authors.forename: Aimee O
authors.initials: AO
authors.lastname: Hersh
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Arkin
authors.forename: Sampath
authors.initials: S
authors.lastname: Prahalad
mesh_terms: D020022:Genetic Predisposition to Disease; D006801:Humans; D007125:Immunogenetics / Q000639:trends; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008178:Lupus Erythematosus, Cutaneous / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D058990:Molecular Targeted Therapy / Q000639:trends*; D012867:Skin / Q000473:pathology*
chemical_list: D007166:Immunosuppressive Agents